#USA #New York #Pomerantz LLP #Aquestive Therapeutics #AQST

Pomerantz Law Firm Issues Investor Alert Regarding Aquestive Therapeutics Class Action

Pomerantz LLP, well-known for its leadership in securities class action litigation, has announced the filing of a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST). This lawsuit pertains to allegations of securities fraud and other unlawful business practices involving the company and its officers or directors. Investors who have incurred losses during their investments in Aquestive are encouraged to take note of the impending deadlines.

The firm calls for any affected investors to reach out to Danielle Peyton of Pomerantz LLP, either via email or phone, to discuss their potential participation in the lawsuit. The contact number for the firm is toll-free, providing a direct line for those wishing to engage legally.

According to the details of the lawsuit, the allegations came to light following an announcement by Aquestive on January 9, 2026. The company disclosed that it received a correspondence from the U.S. Food and Drug Administration (FDA) highlighting deficiencies in its application for the Anaphylm, a sublingual film treatment. The letter confirmed that the FDA's review was ongoing, which has indefinitely delayed potential approval for this product.

This revelation significantly impacted the company's stock, which saw a severe decline of $2.30 per share, translating to a shocking 37.04% drop within the same trading day. For many investors, this drop could translate into considerable financial losses, justifying the legal actions pursued by Pomerantz LLP.

Investors with stakes in Aquestive Therapeutics during the class period have until May 4, 2026, to act if they wish to have their voices heard in court proceedings. The firm encourages potential class members to express their interest in officially becoming lead plaintiffs by obtaining a copy of the complaint from Pomerantz's website.

Pomerantz LLP has spent over 85 years in the field of corporate, securities, and antitrust class litigation. The firm was established by Abraham L. Pomerantz, widely regarded as the pioneer in securities class actions. Over the decades, it has fought vigorously for the rights of investors against fraud and corporate misconduct, securing millions of dollars in settlements for class members. The firm’s reputation solidifies its position as a trusted ally for investors facing losses due to alleged corporate misdeeds.

As investors face a turbulent environment, understanding the implications of class action suits, such as the one against Aquestive Therapeutics, could crucially inform their decisions moving forward. Stakeholders are encouraged to stay updated and take appropriate actions to protect their rights and investments.

This alert serves as a reminder of the necessity for vigilance and proactive engagement regarding investments, especially in the wake of corporate announcements that can have unexpected and significant consequences on stock prices.

Investors seeking more information about this case or other similar actions can visit the Pomerantz website or reach out directly to schedule discussions about their options. As the deadline approaches, time is of the essence for those wishing to engage in this critical legal battle.